1型糖尿病小鼠肝脏的口服葡萄糖代谢及差异表达基因

目的：观察口服葡萄糖在1型糖尿病小鼠肝脏的代谢,比较1型糖尿病小鼠与正常小鼠口服葡萄糖后肝组织基因表达的差异。方法：链脲霉素（STZ）诱导C57雄性小鼠1型糖尿病模型为实验组（n=8）,正常C57雄性小鼠为对照组（n=8）。每组随机取2只,按50ml／kg给予4％葡萄糖生理盐水溶液灌胃,2h取肝组织检测基因表达谱（Mouse Genome 430 2．0Array）。每组另6只．同样剂量给予含14C标记葡萄糖。结果：糖尿病小鼠口服14C标记葡萄糖2h后,肝组织同位素水平是正常对照组的4倍。以正常对照组为参比,共有舛条基因的表达变化差异在2倍以上,其中上调基因61个,下调基因33个。根据功能基因组分析,11条差异表达基因与脂代谢、胆固醇代谢相关,其中7条上调基因与脂、胆固醇合成相关,1条下调基因与脂肪酸分解相关。结论：SIZ诱导的1型糖尿病小鼠口服葡糖后2h,肝脏脂、胆固醇合成相关基因表达增高。     

利用生物信息学研究肥胖与2型糖尿病患者肝组织基因表达变化

目的:利用芯片数据分析工具对GEO基因芯片数据进行数据挖掘,系统分析肥胖与2型糖尿病患者肝组织相关基因表达的变化,探讨肥胖与2型糖尿病的联系及糖尿病早期预防和诊断的新靶点。方法:首先在公共芯片数据库中选择肥胖与2型糖尿病相关芯片数据(GSE15653),利用R等芯片数据分析工具分析肥胖与2型糖尿病患者肝组织基因的表达变化,并预测相关差异表达基因在血中蛋白表达。结果:肥胖患者与正常人肝组织比较发现412个差异表达基因,其中上调表达基因212个,下调表达基因200个,2型糖尿病患者中控制良好者与正常人肝组织比较发现486个差异表达基因,其中上调表达基因253个,下调表达基因233个,而2型糖尿病患者中控制不良者与正常人肝组织比较发现1051个差异表达基因,其中上调表达基因560个,下调表达基因491个;2型糖尿病控制良好者与肥胖患者肝组织有263个相同的表达变化基因,而2型糖尿病控制不良者与肥胖患者肝组织有131个相同的表达变化基因;结合蛋白质组学结果分析肥胖与2型糖尿病相关的差异表达基因中有30个蛋白表达产物是分泌型蛋白。结论:肥胖及2型糖尿病患者肝组织与正常肝组织比较基因表达均发生明显变化,其基因表达变化数目随疾病的严重性增加而增多,而且2型糖尿病的控制情况与肝组织基因表达变化有密切关系。肥胖与2型糖尿病相关的差异表达基因中表达分泌型蛋白的可进一步用于研发监测疾病发生发展的候选靶分子。     

不同生存条件下东方田鼠肝脏基因表达谱分析

目的比较实验室条件下饲养的东方田鼠和野外捕捉东方田鼠肝脏的基因表达差异,寻找可能参与肝脏病变的关键基因。方法以实验室条件饲养的东方田鼠和野外捕捉东方田鼠为研究对象,分别抽提RNA,逆转录成cDNA,体外转录为cRNA并进行片段化;利用表达谱芯片分别进行杂交,扫描后筛选差异基因,并应用real-time PCR方法对部分基因的表达水平进行进一步测定,验证芯片数据的结果。结果实验室饲养东方田鼠肝组织与野外捕捉东方田鼠相比,共有99个基因和41个EST差异表达。其中参与机体代谢的基因占主导,约占35.4%;其次为参与信号通路的基因,约占24.2%;参与细胞周期和免疫的基因分别占6.1%和3.0%。结论利用基因表达谱芯片初步筛选了可能参与东方田鼠脂肪肝形成过程的基因,发现机体代谢通路的基因占主导,肝脏中细胞色素家族基因表达差异明显。     

smc5基因敲除斑马鱼肝脏转录组学分析

摘要 目的：探讨smc5基因敲除对斑马鱼肝脏基因表达谱的影响,进一步明确smc5突变对斑马鱼代谢的影响。方法：用CRISPR/Cas9技术构建smc5基因敲除斑马鱼模型,取3个月的smc5^-/-和野生型斑马鱼肝脏进行转录组测序,创建基因表达谱文库,观察smc5基因敲除后斑马鱼肝脏基因表达谱的变化,将筛选出的差异表达基因进行功能富集,并运用荧光定量PCR对KEGG通路中显著的差异表达基因进行验证。结果：成功构建出7号外显子上2碱基缺失造成移码突变的smc5基因敲除斑马鱼模型。RNA-seq发现smc5^-/-斑马鱼的肝脏基因表达谱变化显著,包含p53的多个通路激活,如细胞周期和凋亡。糖酵解、脂肪酸降解与代谢、丙酮酸代谢等相关通路显著下调。荧光定量PCR结果与RNA-seq结果一致。结论：smc5基因敲除下调斑马鱼肝脏糖脂代谢。本研究结果为进一步研究SMC5基因在糖脂代谢调控中的潜在机制奠定基础。     

MAPK信号通路基因在小鼠肝再生中的表达谱变化

为了分析丝裂原活化蛋白激酶(Mitogen-Activated Protein Kinases,MAPK)信号通路基因在肝再生中的表达图谱,以及探讨MAPK信号通路在肝再生中的作用,文章利用四氯化碳(Carbon Tetrachloride,CCl4)诱导的小鼠肝损伤再生模型对MAPK信号通路基因的表达进行检测.首先,采用CCl4腹腔注射的方法建立小鼠肝损伤再生模型,通过肝脏切片HE染色和测定血清中谷丙转氨酶活性确认模型的质量,然后,在注射CCl4后的第0、0.5、1.5、4.5、7 d分别采集小鼠肝脏样本,应用Affymetrix公司的小鼠基因表达芯片,检测MAPK信号通路中93个基因的差异表达图谱,并用荧光实时定量PCR法验证芯片检测的结果.结果表明,在芯片检测到的93个MAPK信号通路基因中,有31个在肝再生中有不同程度差异表达,且经荧光实时定量RT-PCR检测的结果与基因芯片的结果相符合.基因表达谱芯片技术可以筛选出肝再生中差异表达的基因,在小鼠肝再生中的第0.5和1.5 d,MAPK信号通路中表达水平上调的基因增多,而在第4.5和7 d,则表达水平下调的基因明显增多.这一结果表明MAPK信号通路对肝再生不同阶段的双重调控作用.     

2型糖尿病早期大鼠外周神经节基因表达谱分析

糖尿病神经病变(Diabetic neuropathy,DN)是糖尿病在神经系统发生的多种并发病变的总称。文章旨在筛选2型糖尿病早期大鼠外周神经节差异表达的基因。采用Illumina大鼠基因表达芯片,比较糖尿病模型与非糖尿病大鼠外周神经节基因表达谱差异。结果表明,全基因组12 604个已知基因中,158个基因差异表达。糖尿病组与非糖尿病组相比,87个基因表达上调,71个表达下调。对差异表达的基因进行GO分析,发现上调基因所参与的最显著(P<0.001)的几个生物学过程都与神经细胞骨架及运动功能有关;下调基因所参与的最显著的生物学过程主要与"对病毒/生物刺激/其它生物的反应"有关。KEGG(Kyoto encyclopedia of genes and genomes)分析显示,差异表达的基因所参与的最显著(P<0.001)的生物学通路为代谢通路。结果表明:高血糖可导致糖尿病大鼠外周神经节代谢紊乱;高血糖可能通过免疫炎症反应、改变神经细胞骨架及运动功能相关的基因的表达,继而损害外周神经节的结构和功能。     

哇巴因作用于血管内皮细胞的基因表达谱分析

目的:研究0.3 nmol/L哇巴因(ouabain)作用下血管内皮细胞的基因谱改变.方法:以包含8464条人类基因的DNA芯片检测血管内皮细胞受0.3 nmol/L哇巴因活化后的基因表达谱.结果:血管内皮细胞受哇巴因作用2 h后,340条基因出现表达差异,其中上调的共有145 条,多数与细胞代谢和转录调控相关.结论:提示哇巴因可能参与血管内皮细胞的正常生长代谢.     

Affymetrix基因表达谱芯片在新疆维吾尔族与汉族胰腺癌组织样本间差异表达基因筛选中的运用

目的:运用基因表达谱芯片筛选并分析新疆维吾尔族与汉族胰腺癌组织样本间的差异表达基因。方法:收集我院2014年1月至2016年6月间行手术切除的维吾尔族与汉族胰腺导管细胞癌组织并提取总RNA,选取经Nanodrop 2000与Agilent 2100仪器质检合格的样本总RNA采用Affymetrix基因表达谱芯片筛选出差异表达基因并绘制统计图,运用基因本体(GO)分析及信号通路(Pathway)分析对这些差异表达基因的生物信息进行汇总分析。结果:通过基因表达谱芯片分析,新疆维吾尔族与汉族胰腺癌组织样本间共检测到1063个基因存在差异表达,在维吾尔族胰腺癌标本中显著上调表达的基因共281个,差异表达倍数最高的为IGLV1-44基因(差异倍数:9.99)下调表达的基因共782个,差异表达倍数最高的为CPB1基因(差异倍数:33.76);在Gene Ontology数据库中共检索到815个上述差异表达基因具有明确的GO分类,差异表达倍数最高的为CPB1基因(差异倍数:33.76);Pathway分析中共检测到30条信号通路包含有上述差异表达基因,共涉及196个基因,其中以FAK信号通路差异表达基因富集程度最高,差异表达倍数最高的基因为COL11A1基因(差异倍数:5.02)。结论:基因表达谱芯片分析结果显示,在新疆维吾尔族与汉族胰腺癌组织样本间存在大量的差异表达基因,这些基因与胰腺癌的增殖分化、侵袭转移及多药耐药等特性密切相关,且参与了多条生物体内重要信号转导通路的调控。     

食管组织和外周血中代谢和DNA修复相关基因的表达谱分析

目的:研究代谢酶和DNA修复相关基因在食管组织和外周血中的表达谱.方法:收集93例淮安地区食管癌病例的食管癌旁正常组织和外周血,采用实时荧光定量RT-PCR方法定量分析食管正常组织和外周血中的代谢酶和修复酶共计11个基因的mRNA水平.结果:11个代谢酶和修复酶基因在食管组织和外周血的表达水平有明显差异,食管组织中GSTPI＞NQOI、MGMT＞hMLH1、hMSH2、hOGG1、XRCC1、XPD,XPA、CYP2E1＞MTHFR;在外周血中GSTP1＞hMLH1、hMSH2、XPA、MGMT＞hOGG1、NQO1、CYP2E1、XRCC1、XPD＞MTHFR.食管组织基因表达水平与外周血相应基因的表达之间未发现有统计学意义的直线相关关系.结论:代谢酶和修复酶基因在食管组织和外周血的表达谱相似,但基因表达水平有差异,本分析为这些基因的研究提供了基础数据的支持.外周血和食管组织在肿瘤易感性和肿瘤发生相关的生物标志物研究中具有不同的应用价值.     

胰岛素受体底物1和2敲低对猪肝脏细胞糖脂代谢的影响

目的:通过shRNA干扰高效敲低猪肝脏细胞中IRS1和IRS2基因的表达,进而验证其对于糖脂代谢相关基因表达的影响,为构建2型糖尿病模型猪奠定基础。方法:首先通过重叠PCR方法克隆了猪IRS1基因全部的mRNA序列(4 814bp)以及通过3'RACE方法克隆了猪IRS2基因的部分3'非编码区(3-untranslated region,3'UTR)。然后,通过Real-time PCR筛选获得了能显著敲低这两个基因的shRNA片段,并在同时敲低IRS1和IRS2的猪肝脏细胞中,检测糖脂代谢相关基因的表达。结果:猪肝脏细胞中IRS1和IRS2的表达被显著敲低,分别下降了78%和64%。另外,糖异生作用酶磷酸烯醇丙酮酸激酶(phosphoenolpyruvate carboxykinase,PEPCK)和果糖-1,6-二磷酸酶(fructose-1,6-bisphosphatase,F-1,6-BP)基因表达显著上升,并导致催化肝脏中糖酵解反应的葡糖激酶(glucokinase,Gck)基因表达的显著下降。同时,胆固醇调节元件结合蛋白(sterol regulatory element-binding proteins,SREBP-1)基因的表达也显著上升以及胆固醇调节基因Abcg8,CYP7a1表达明显上调。结论:猪肝脏细胞中IRS1和IRS2基因的敲低可激活糖异生作用,并抑制糖酵解反应,从而导致糖代谢的异常,同时也能引起脂类代谢的异常。     

Gene Expression Profile Analysis of Type 2 Diabetic Mouse Liver

Liver plays a key role in glucose metabolism and homeostasis, and impaired hepatic glucose metabolism contributes to the development of type 2 diabetes. However, the precise gene expression profile of diabetic liver and its association with diabetes and related diseases are yet to be further elucidated. In this study, we detected the gene expression profile by high-throughput sequencing in 9-week-old normal and type 2 diabetic db/db mouse liver. Totally 12132 genes were detected, and 2627 genes were significantly changed in diabetic mouse liver. Biological process analysis showed that the upregulated genes in diabetic mouse liver were mainly enriched in metabolic processes. Surprisingly, the downregulated genes in diabetic mouse liver were mainly enriched in immune-related processes, although all the altered genes were still mainly enriched in metabolic processes. Similarly, KEGG pathway analysis showed that metabolic pathways were the major pathways altered in diabetic mouse liver, and downregulated genes were enriched in immune and cancer pathways. Analysis of the key enzyme genes in fatty acid and glucose metabolism showed that some key enzyme genes were significantly increased and none of the detected key enzyme genes were decreased. In addition, FunDo analysis showed that liver cancer and hepatitis were most likely to be associated with diabetes. Taken together, this study provides the digital gene expression profile of diabetic mouse liver, and demonstrates the main diabetes-associated hepatic biological processes, pathways, key enzyme genes in fatty acid and glucose metabolism and potential hepatic diseases.     

Regulation of adiponectin receptor gene expression in diabetic mice

Adiponectin is an adipocyte-derived factor that plays pivotal roles in lipid and glucose metabolism in muscle and liver. The following two adiponectin receptor types were recently identified: AdipoR1 is abundantly expressed in muscle, whereas AdipoR2 is predominantly expressed in the liver. To clarify the regulation of adiponectin receptor gene expression in diabetic states, we examined mRNA levels of AdipoR1 in the muscles of diabetic animals by Northern blotting. The level of AdipoR1 mRNA was increased approximately 2.5-fold in muscle of streptozotocin (STZ) diabetic mice, but the normal level was restored by insulin administration, indicating that insulin has an inhibitory effect on AdipoR1 expression. To confirm this inhibitory effect of insulin, we performed in vitro experiments using C2C12 skeletal muscle cells. Insulin treatment for 24 h decreased AdipoR1 expression by approximately 60% in C2C12 cells. In addition, this effect was mediated by the phosphatidylinositol 3-kinase-dependent pathway rather than the mitogen-activated protein kinase pathway. AdipoR1 expression in insulin-resistant diabetic mice was also investigated. AdipoR1 expression was decreased by 36% in type 2 diabetic obese db/db mice compared with lean mice. In contrast, hepatic AdipoR2 expression was not significantly changed in either STZ mice or genetically obese mice. Our results indicate that regulation of AdipoR1, but not that of AdipoR2, may be involved in glucose and lipid metabolism in diabetic states.     

Glutamine: fructose-6-phosphate amidotransferase activity and gene expression are regulated in a tissue-specific fashion in pregnant rats.

We examined whether regulation of glutamine: fructose-6-phosphate amidotransferase (GFA), the rate-limiting enzyme of the hexosamine pathway, is tissue specific and if so whether such regulation occurs at the level of gene expression. We compared GFA activity and expression and levels of UDP-hexosamines and UDP-hexoses between insulin-sensitive (liver and muscle) tissues and a glucose-sensitive (placenta) tissue from 19 day pregnant streptozotocin diabetic and non-diabetic rats. In pregnant non-diabetic rats GFA activities averaged (1521+/-75 pmol/mg protein x min) in the placenta, 895+/-74 in the liver and 81+/-11 in muscle (p<0.001 between each tissue). In the diabetic rats, GFA activities were approximately 50% decreased both in the liver (340+/-42 pmol/mg protein x min, p<0.05 vs control rats) and in skeletal muscle (46+/-3, p<0.05) compared to control rats. In the placenta, GFA activities were identical between diabetic (1519+/-112 pmol/mg protein x min) and non-diabetic (1521+/-75) animals. In the liver, the reduction in GFA activity could be attributed to a significant decrease in GFA mRNA concentrations, while GFA mRNA concentrations were similar in the placenta between diabetic and non-diabetic animals. UDP-N-acetylglucosamine (UDP-GlcNAc), the end product of the hexosamine pathway, was significantly reduced in the liver and in skeletal muscle but similar in the placenta between diabetic and non-diabetic rats. In summary, GFA activity and expression and the concentration of UDP-GlcNAc are decreased in the liver but unaltered in the placenta, although GFA activity is almost 2-fold higher in this tissue than in the liver. These data provide the first evidence for tissue specific regulation of GFA and for its regulation at the level of gene expression.     

Activation of the hexosamine pathway causes oxidative stress and abnormal embryo gene expression: involvement in diabetic teratogenesis

BACKGROUND: Oxidative stress is critical to the teratogenic effects of diabetic pregnancy, yet the specific biochemical pathways responsible for oxidative stress have not been fully elucidated. The hexosamine pathway is activated in many tissues during diabetes and could contribute to oxidative stress by inhibiting the pentose shunt pathway, thereby diminishing production of the cellular antioxidant, reduced glutathione (GSH). METHODS: To test the hypothesis that activation of the hexosamine pathway might contribute to the teratogenic effects of diabetic pregnancy, pregnant mice were injected with glucose, to induce hyperglycemia, or glucosamine, to directly activate the hexosamine pathway. Embryo tissue fragments were also cultured in physiological glucose, high glucose, or physiological glucose plus glucosamine, to test effects on oxidative stress and embryo gene expression. RESULTS: Glucosamine increased hexosamine synthesis and inhibited pentose shunt activity. There was a trend for transient hyperglycemia to have the same effects, but they did not reach statistical significance. However, both glucose and glucosamine significantly decreased GSH, and increased oxidative stress, as indicated by 2',7'-dichloro-dihydrofluorescein fluorescence. Glucose and glucosamine inhibited expression of Pax-3, a gene required for neural tube closure both in vivo and in vitro, and increased neural tube defects (NTDs) in vivo; these effects were prevented by GSH ethyl ester. High glucose and glucosamine inhibited Pax-3 expression by embryo culture, but culture in glutamine-free media to block the hexosamine pathway prevented the inhibition of Pax-3 expression by high glucose. CONCLUSIONS: Activation of the hexosamine pathway causes oxidative stress through depletion of GSH and consequent disruption of embryo gene expression. Activation of this pathway may contribute to diabetic teratogenesis.     

急、慢性运动对2型糖尿病大鼠脂肪PI3K/AKT/GLUT4通路的影响

目的:探讨急性和慢性运动对2型糖尿病(T2DM)大鼠脂肪组织明磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(AKT)/葡萄糖运载体4(GLUT4)信号通路的影响。方法:15月龄SD雄性大鼠52只随机分为正常对照组(n=13)和高脂组(n=39),分别喂养普通和高脂饲料。8周后,高脂组体重＞正常对照组20％,注射小剂量STZ后,血糖＞16.7 mmol/l,造模成功。将糖尿病模型组随机分为糖尿病对照组(DC,n=13),糖尿病慢性运动组(DCE,n=13),糖尿病急性运动组(DAE,n=13)。DCE组进行8周的游泳运动,DAE组进行一次性游泳运动。测定血脂,血糖和血清胰岛素,Western blot法测定脂肪PI3K、AKT和GLUT4蛋白含量。结果:糖尿病组体重、血脂、血糖、胰岛素显著高于正常对照组(P均＜0.01);高密度脂蛋白胆固醇(HDL-C)水平降低(P＜0.05),脂肪组织中PI3K、AKT和GLUT4蛋白表达下降(P均＜0.01)。糖尿病慢性运动组体重、血脂、血糖、胰岛素均出现显著性下降(P均＜0.01);HDL-C升高(P＜0.05),脂肪PI3K、AKT和GLUT4蛋白表达上升(P＜0.01)。糖尿病急性运动组血脂、血糖、胰岛素下降(P均＜0.05);HDL-C升高(P＜0.05),脂肪PI3K、AKT和GLUT4含量显著上升(P均＜0.05)。结论:①高脂饮食结合小剂量STZ诱导的T2DM大鼠脂肪组织PI3K/AKT通路受损,降低了胰岛素的敏感性。②急性、慢性有氧运动,均可以通过PI3K/AKT通路,改善糖脂代谢紊乱,慢性运动略优于急性运动。     

Green tomato extract attenuates high-fat-diet-induced obesity through activation of the AMPK pathway in C57BL/6 mice

Obesity is a risk factor for numerous metabolic disorders. Recently, natural compounds that may be beneficial for improving obesity have received increasing attention. In this study, we investigated whether red and green tomato extracts attenuate high-fat-diet-induced obesity in C57BL/6 mice. The mice were maintained on a normal diet (ND) or high-fat diet (HFD) for 4 weeks and then fed ND, HFD, HFD plus 2% red tomato extract (RTE) or HFD plus 2% green tomato extract (GTE) for 13 weeks. The weekly food intakes among the groups were not significantly different. Body weight of mice fed HFD plus GTE was significantly decreased to the level of mice fed ND, but the body weight was only slightly reduced in mice fed HFD plus RTE. Epididymal adipose tissue and liver weights were significantly decreased in mice fed HFD plus GTE compared to those in HFD. Serum total cholesterol and low-density lipoprotein cholesterol levels in mice fed GTE were modestly reduced, and liver total cholesterol level was strongly decreased in HFD plus GTE-fed mice compared to that in HFD-fed mice. Adenosine-monophosphate-activated protein kinase (AMPK) and acetyl-CoA carboxylase phosphorylation in liver from HFD plus GTE-fed mice was significantly elevated, and HMG-CoA reductase expression was also significantly decreased. GTE strongly decreased the expression of peroxisome proliferator-activated receptor gamma, CCAAT/enhancer-binding protein alpha and perilipin in the adipose tissue of mice fed HFD plus GTE. Our results indicate that the antiobesity effects of GTE may be associated with activation of the AMPK pathway.     

Protein-rich extract of <Emphasis Type="Italic">Musca domestica</Emphasis> larvae alleviated metabolic disorder in STZ-induced type 2 diabetic rat model via hepatoprotective and pancreatic β-cell protective activities

The study was designed to explore the beneficial effect of Musca domestica larvae extract (MDLE) on a metabolic disorder using a diabetic rat model. Streptozotocin-induced diabetic rats were treated with or without MDLE. Blood glucose, insulin levels, lipid profiles, and oxidative stress markers were measured. The morphological changes in the pancreas and liver were determined, as well as insulin expression. The expression of glucose transporter 4 (GLUT4), phospho-adenosine monophosphate-activated protein kinase (p-AMPK)/total AMPK, superoxide dismutase 1 (SOD1), catalase (CAT), and peroxisome proliferator-activated receptor gamma (PPARγ) were detected. Compared with untreated diabetic rats, MDLE-treated rats had decreased urine volume, food intake, and water intake, along with significantly lower levels of blood glucose, malondialdehyde (MDA), plasma triglycerides, low-density lipoprotein (LDL), and total cholesterol. MDLE-treated rats also had higher levels of SOD activity, high-density lipoprotein (HDL), and insulin. MDLE treatment partially restored the β-cell population, improved the liver necrosis and islet cell damage, reversed the decreased expression of GLUT4, phospho-AMPK, SOD1, and CAT in the liver, skeletal muscle and pancreatic tissue, and also increased the expression of PPARγ in the liver and adipose tissue in diabetic rats. In conclusion, the obtained results suggest that MDLE could possibly be used pharmacologically as an adjuvant for the treatment of diabetes.